Introduction
Over the past twenty years, considerable progress has been achieved in understanding the molecular genetics of cancer formation. Genetic alterations in oncogenes and tumor suppressor genes occur consistently in many tumor types and experiments have shown that such mutations can have a potent growth promoting eect. Mutations in the oncogenes may constitutively activate cellular proto-oncogenes so that they are refractory to regulation. The activated oncogene generally behaves in a dominant manner in that its growth promoting eects can be maintained in the presence of a normal proto-oncogene allele. In contrast, tumor suppressor mutations in tumors are recessive in nature. Inactivation or mutation of one allele is usually accompanied by loss or mutation of the second allele in sporadically arising tumors. Inherited cancer predisposition syndromes are often characterized by the germ line transmission of a single defective tumor suppressor allele in the aected families. Not surprisingly, the likelihood of an aected individual incurring a mutation in the remaining wild type tumor suppressor allele and developing a tumor is much higher than for the normal individual with two intact alleles.
The use of small animals for modeling tumors in a controlled experimental manner has been a mainstay of cancer research for almost a century. However, the development of molecular genetic techniques to identify speci®c cancer-associated gene lesions, combined with breakthroughs in the manipulation of the germ line of mice, have greatly facilitated the generation of powerful new models for understanding the mechanistic roles of speci®c genes in cancer initiation and progression. The development of transgenic mice in the 1980s through zygote pronuclear injection methods has allowed the addition of any cloned gene to the germ line of mice to determine the eects of the added gene on the resulting phenotype (Palmiter and Brinster, 1986) . Usually, the introduced exogenous gene is driven by a promoter which restricts expression of the transgene to a speci®c tissue compartment. This approach particularly lends itself to the analysis of the tumor promoting functions of dominant acting oncogenes, which can be expressed in speci®c tissues and might induce tumors within that tissue within a relatively short time frame (Hanahan, 1989) . A large number of very useful mouse cancer models have been developed via this approach (Hanahan, 1989; Bedell et al., 1997) .
The recessive nature of tumor suppressors precluded study of their in vivo eects through standard transgenic approaches, however. Rather than constitutively expressing an activated oncogene, it would be necessary to inactivate one or both endogenous tumor suppressor alleles in order to study their role in cancer promotion. This was a more challenging task, but the development of mouse embryonic stem cell gene targeting techniques has made such an approach feasible. Inactivation of endogenous tumor suppressor genes in the germ line of mice has been achieved for virtually every known tumor suppressor gene originally identi®ed in humans (Jacks, 1996; Bedell et al., 1997; .
The advantages of such tumor suppressor`knockout' mice have been multiple. First, the heterozygous version of a particular tumor suppressor knockout mouse may provide a useful animal model for the corresponding human cancer predisposition syndrome. While there have been a number of successes in this regard, the inherent dierences between mouse and human have resulted in some incongruities. For example, mice heterozygous for the Rb gene develop pituitary adenomas rather than the retinoblastomas typically observed in children with a defective germ line Rb allele Hu et al., 1994) . Nevertheless, the Rb heterozygous mice do develop early tumors and thus have provided a number of important insights into the role of Rb in tumorigenesis.
A second advantage provided by the homozygous knockout mice (and not obtainable by cell culture or human tumor studies) has been the important insights into the role of tumor suppressors in embryonic development. The well characterized embryology of the mouse has facilitated these studies. With a few notable exceptions, mice null for a given tumor suppressor exhibit embryonic lethality and a distinct pattern of organ malformations. Analysis of the biological and molecular bases of the observed defects has facilitated our understanding of the role of particular tumor suppressor genes in organogenesis, regulation of cell cycle control, dierentiation, and apoptosis.
The accumulation of numerous tumor-susceptible transgenic and knockout mice has aided investigators in analysing genetic interactions among the oncogenes and tumor suppressor genes. Intercrossing of two dierent tumor suppressor knockout mice to generate doubly de®cient ospring may reveal dierent levels of cooperativity between the two genes. In some cases embryonic lethality in doubly de®cient mice can be accelerated or delayed. In other situations, tumor incidence rates can be accelerated and tumor spectra altered by the combined tumor suppressor de®ciencies. Important and sometimes surprising new insights can be obtained from such combinations. Crossing the tumor suppressor mutations into inbred strains of dierent backgrounds has also revealed strain-speci®c dierences in tumor development and spectra, allowing for the identi®cation of novel tumor modi®er genes. The identi®cation of such modi®ers (as well as other cooperating oncogenes and tumor suppressor genes) will be greatly assisted by the availability of thousands of strain-speci®c microsatellite markers spanning the mouse genome (Dietrich et al., 1995) .
Another signi®cant bene®t is that primary cells lacking a speci®c tumor suppressor gene can often be derived from the knockout mice embryos (either ES cells or embryonic ®broblasts). Biological or biochemical comparison of various attributes of the null cells and wild type control cells in culture can impart important insights into the function of a given tumor suppressor in preventing transformation and in regulating cell cycle control, growth signal transduction, dierentiation, apoptosis, genomic stability, and response to DNA damage.
The goal of this review is to outline some of the important new insights provided by experiments directly utilizing the tumor suppressor-de®cient mice and cells derived from them. It is not our intention to describe every knockout mouse which exhibits an enhanced tumor predisposition. Rather, we will take a more focused approach employing a useful classification scheme recently proposed by Kinzler and Vogelstein (1998) . They have subdivided the tumor suppressors into two groups, the`gatekeepers' and thè caretakers'. The gatekeepers directly regulate tumor cell growth (usually through cell cycle control mechanisms), while the caretakers (often DNA repair genes) are thought to increase genetic instability in a manner which indirectly promotes cell growth through an increased mutation rate. Our focus will be on the gatekeeper genes associated with well characterized inherited cancer predisposition syndromes in humans. We will describe the tumor phenotypes observed in the tumor suppressor-de®cient mice and we will assess the usefulness of some of these tumor suppressor knockout mice as models for the corresponding human cancer syndrome. It is not our intention to provide an exhaustive review, but rather to highlight some of the contributions that such mice have made to our basic understanding of tumor suppressor function.
p53-de®cient mice (Li-Fraumeni syndrome)
Discovered in 1979 as a cellular protein complexed with a DNA tumor virus oncoprotein (Lane and Crawford, 1979; Linzer and Levine, 1979) , early studies suggested that the p53 gene might encode a proto-oncogene, as mutant versions of p53 had oncogenic activity in transformation assays (Jenkins et al., 1984; Eliyahu et al., 1984; Parada et al., 1984) . However, by 1989, several groups had demonstrated that the wild type p53 gene encodes a tumor suppressor protein (Finlay et al., 1989; Eliyahu et al., 1989; Baker et al., 1990; Chen et al., 1990; Mercer et al., 1990) . Transfection of p53 into cultured cells inhibited transformation mediated by a variety of oncogenes, while Vogelstein and others had shown that a number of human tumors displayed mutation or loss of both p53 alleles (Masuda et al., 1987; Nigro et al., 1989; Baker et al., 1989) . The subsequent demonstration that a high fraction of individuals aected by a familial cancer predisposition called Li-Fraumeni syndrome had germ line p53 mutations solidi®ed the status of p53 as a tumor suppressor (Malkin et al., 1990; Srivastava et al., 1990) . Since these initial reports, thousands of papers have been published demonstrating that the p53 gene is the most frequently mutated gene in a wide variety of human cancers (for reviews, see Gottlieb and Oren, 1996; Ko and Prives, 1996; Levine, 1997; Moll and Schramm, 1998) . p53 may suppress tumorigenesis through multiple mechanisms. It has been shown that various cellular stresses, including DNA damage, hypoxia, depletion of ribonucleotide pools, serum starvation, and aberrantly activated oncogenes, may induce stabilization of p53 through phosphorylation of speci®c sites on p53, preventing it from binding to the mdm2 protein which facilitates its degradation (Prives, 1998) . Stabilized p53 can induce either G1 cell cycle arrest or apoptosis (Kastan et al., 1992; Yonish-Rouach et al., 1991; Lane, 1992) . The decision by p53 about whether to intiate an arrest program or an apoptotic program can be in¯uenced by a number of variables, including cell type, cytokine or growth factor concentrations, levels of p53, or amount of damage (Ko and Prives, 1996) . Whether arrest or apoptosis is induced, the end result is that the cell with DNA damage is prevented from replicating damaged DNA templates and incurring potentially oncogenic DNA lesions.
The cell cycle arrest function of p53 is mediated largely by its ability to transcriptionally regulate an extensive array of growth regulatory genes by both positive and negative mechanisms (Ko and Prives, 1996; Levine, 1997) . Positive transcriptional regulation by p53 is through speci®c DNA binding to sites upstream or within the target genes. Important targets of p53 upregulation include p21
, a G1 cyclindependent kinase inhibitor, mdm2, a negative regulator of p53 function, and IGF-BP3, an anti-mitogenic factor (el-Deiry et al., 1993; Barak et al., 1993; Buckbinder et al., 1995) . Important transcriptional targets implicated in apoptosis include bax, KILLER/ DR5, and FAS/Apo1 (Miyashita et al., 1995; Owen-Schaub et al., 1995) . As might be expected, those genes repressed by p53 include positive growth regulators, including PCNA and bcl-2 (Deb et al., 1992; Miyashita et al., 1994) .
In addition to its role in mediating G1 checkpoint control, p53 has also been implicated in G2/M checkpoints (Levine, 1997) . Mouse ®broblasts and spleen cells de®cient in p53 undergo multiple rounds of DNA synthesis without completing chromosome segregation, forming tetraploid and octaploid cells (Cross et al., 1995) . p53 seems to be an integral part of the process that regulates the number of centrosomes in a cell. Mouse ®broblasts from p53 null mice produce abnormal numbers of centrosomes after a few doublings in cell culture and initiate spindles with three or four poles (Fukasawa et al., 1996) . Thus, preservation of global genomic stability has been shown to be an important function of p53, as multiple assays have shown that cells missing it display more frequent genome aberrations of various types Yin et al., 1992 Livingstone et al., 1992) .
p53 may also control a third cell cycle checkpoint (G0/G1) mediated by the growth arrest speci®c (Gas-1) protein which encodes a membrane protein that is highly expressed in growth restricted conditions (G0). Gas-1 can restrict ®broblasts to G0 only when wild type p53 is present (Del Sal et al., 1995) . Consistent with this observation, is that hepatocytes null for p53 also show an increase in G1 cells compared to that with wild type (Yin et al., 1998) . This data suggests that p53 also function to maintain cells in G0, either by facilitating their exiting from M phase or by preventing G0/G1 transition.
Given the importance of the p53 gene in cell cycle control and cancer prevention, development of a mouse model was an obvious priority. Several groups have been successful in developing p53-de®cient mice using gene targeting in embryonic stem cells (Donehower et al., 1992; Gondo et al., 1994; Purdie et al., 1994; Tsukada et al., 1993) . The majority of p53 null mice develop normally. However, a fraction of the female null embryos display defects in neural tube closure resulting in an overgrowth of neural tissue in the region of the mid-brain, a condition known as exencephaly (Armstrong et al., 1995; Sah et al., 1995) .
Not surprisingly, p53 null mice develop tumors at a very young age. By 6 months of age, 75% of p537/7 mice have developed tumors of various types and all have succumbed to tumors by 10 months of age (Donehower et al., 1992) . Thymic T-cell lymphomas are the most frequently arising tumor type in the null mice, but lymphomas of B-cell origin, soft tissue sarcomas, osteosarcomas, testicular teratomas, and other types are also observed (Donehower et al., 1992; Purdie et al., 1994; . The p53 heterozygous (p53+/7) mice are also susceptible to tumors, but these neoplasms arise later than those observed in the p537/7 mice. Tumors are rarely observed until nine months of age, but by 18 months, roughly 50% have developed cancers, and by 24 months, over 95% of the animals have had tumors or died . This contrasts to a 20% death or tumor incidence in wild type animals of the same strain (primarily C57BL/6) by 24 months. The tumor spectrum in p53+/7 animals diers from that of the p537/7 mice, with osteosarcomas and soft tissue sarcomas being more prevalent than lymphomas (Harvey et al., 1993; . Moreover, carcinomas occur more frequently in the p53+/7 animals.
One issue with respect to the p53+/7 mice is whether their observed tumor incidence and spectrum accurately models the incidence and spectrum of tumors observed in Li-Fraumeni syndrome lineages. The correlation between mouse model and human syndrome in this case is reasonably close. On a life span basis, a 50% tumor incidence in mice by 18 months of age (a mouse life span is 30 ± 36 months) is not very dissimilar from a 50% tumor incidence in aected Li-Fraumeni patients by 30 years of age (Malkin et al., 1990) . Moreover, the tumor types observed in mice, soft tissue sarcomas, osteosarcomas, and lymphomas, are also signature tumors often seen in Li-Fraumeni families (Malkin, 1994) . However, the spectrum concordance is not complete, as the frequent breast and brain tumors seen in Li-Fraumeni patients are infrequently observed in p53+/7 mice.
A central feature of a tumor suppressor is its recessiveness. Thus, inactivation of both copies of a tumor suppressor is considered to be a prerequisite for cancer formation, as originally postulated in Knudson's`two hit' model for tumor suppressors (Knudson, 1971 (Knudson, , 1985 . Indeed, this rule is observed for p53 in most sporadically arising tumors, where point mutation in one allele is often accompanied by the loss of the second allele (Baker et al., 1990) . Surprisingly, however, when the fate of the remaining wild type p53 allele in tumors arising in p53+/7 mice was investigated, we found that this allele is retained structurally intact in about 50% of the tumors as measured by Southern blot hybridization analysis and DNA sequencing . Tests of p53 function in these tumors with retained p53 also indicated that the wild type p53 retained normal transcriptional regulation and apoptosis induction activities. Interestingly, an extensive survey of LiFraumeni tumors has revealed that roughly half of these appear to retain an intact wild type p53 allele (Varley et al., 1997) . Thus, p53 may be an exception to the two hit model in that the mere reduction of p53 dosage level may be sucient to promote cancer formation .
Another interesting issue with respect to such mouse models is the issue of strain-dependent dierences in tumorigenesis. The p537/7 and p53+/7 mice of 129/Sv background develop tumors sooner on average than do their counterparts of predominantly C57BL/6 background (Donehower et al., 1995a) . Moreover, in the C57BL/6 p537/7 mice, the predominant tumor type is lymphoma, whereas in the null 129/Sv strain, testicular teratomas are as common as lymphomas. The dramatic susceptibility of 129/Sv null mice to testicular tumors may be attributed to the fact that wild type mice of this strain have a modest susceptibility to this tumor (Stevens and Little, 1954) . Thus, absence of p53 may exacerbate a previous tumor predisposition.
Despite its usefulness, the p53-de®cient mouse as a model to obtain mechanistic insights into the role of p53 loss in tumorigenesis has certain limitations. Among them are the diverse array of tumors observed and the paucity of control tumors which arise in the p53+/+ littermates in order to form a reliable comparison of p53-dependent and p53-independent tumorigenesis pathways. To circumvent these inherent limitations, a number of investigators have crossed the p53-de®cient mice to transgenic mice that are susceptible to a single tumor type. The ospring of such crosses often develop tumors in a single tissue in a relatively short amount of time. Moreover, the same tumor types with normal (p53+/+) and reduced (p53+/7) complements of p53 can be compared to tumors missing p53 (p537/7) for an array of biological, biochemical, and genetic properties.
Since p53 in cell culture studies aects apoptosis, cell proliferation, and genomic stability, it is obvious that such processes could also be aected by p53 in a tumorigenic context. The bitransgenic models cited above have been particularly useful for assessing how the loss of p53 aects tumor initiation and progression. Early experiments with the p53-de®cient mice have shown that normal tissues in the p53 null mice are particularly refractory to radiation-induced apoptosis (Lowe et al., 1993; Clarke et al., 1993) . With respect to tumors, several studies have shown that absence or loss of p53 in a tumor model is accompanied by reduced levels of tumor cell apoptosis (Symonds et al., 1994; Howes et al., 1994; Pan and Griep, 1994) . Symonds et al. (1994) have demonstrated that a transgenic mouse expressing high levels of a SV40 large T antigen fragment that inactivates Rb in the choroid plexus develop slow growing choroid plexus with high numbers of apoptotic cells. When these mice were made null for p53 through crossing to p53-de®cient mice, the choroid plexus tumors developed sooner and grew faster, largely due to greatly reduced tumor cell apoptosis. Similar eects of p53 loss on tumor progression have been observed in other mouse models with Rb de®ciency (Howes et al., 1994; Pan and Griep, 1994) .
Given the involvement of p53 in multiple phases of cell cycle control, it could be expected that tumors missing p53 would show higher rates of tumor cell proliferation than those tumors with intact p53. In fact, at least two tumor models utilizing p53 knockout mice have shown this to be the case (Hundley et al., 1997; Jones et al., 1997) . In one of these models, we crossed mammary tumor susceptible Wnt-1 transgenic mice to p53-de®cient mice (Jones et al., 1997) . Not unexpectedly, mammary tumors from the p537/7 Wnt-1 transgenic female mice arose sooner and grew much faster than those from p53+/+ Wnt-1 transgenic females (Donehower et al., 1995b; Jones et al., 1997) . However, when tumors were assessed for apoptosis and cell proliferation rates, apoptosis rates in the mammary tumors were found to be modest and not aected by p53 status, even in the early preneoplastic stages. In contrast, cell proliferation rates as measured by percentages of tumor cells in S phase and mitosis were signi®cantly increased in the p537/7 Wnt-1 transgenic mammary tumors compared to their p53+/+ counterparts. Similar results have been obtained by Hundley et al. (1997) for an MMTV-c-ras/p53 mammary tumor model.
Another contributing factor to the rapid appearance and growth of tumors missing p53 could be through increased levels of genomic instability in these tumors. Cell culture experiments using both human and murine cells have shown that the absence of p53 consistently confers increased aneuploidy, increased rates of drug induced gene ampli®cation, and abnormal centrosome duplication (Yin et al., 1992 , Livingstone et al., 1992 , Fukasawa et al., 1996 . In the p53-de®cient Wnt-1 transgenic model cited above, we found that that the absence of p53 in a mammary tumor conferred signi®cantly higher rates of aneuploidy and chromosomal copy number aberrations than the mammary tumors which retained wild type p53 (Donehower et al., 1995b) . This correlation of p53 loss with chromosomal instability has also been con®rmed in sarcomas and lymphomas from the p53-de®cient mice .
The various p53-associated tumor models described above are not in complete agreement. It appears in some models that p53 loss results in abrogated tumor cell apoptosis and that this may be a key rate limiting step in tumor progession. In other models, tumor cell apoptosis rates are low and relatively unin¯uenced by p53 status, while cell proliferation rates are dramatically aected by p53 loss. In each model, the results which are observed are probably aected by the cooperating oncogene/tumor suppressor or the tissue type expressing it. The Wnt-1 and MMTV-c-ras transgenes may abrogate apoptosis independently of p53 while inactivated Rb clearly does not. The Wnt-1 and MMTV c-ras models were thus useful in eliminating apoptosis as a tumor variable and allowing the more direct comparison of cell proliferation rates in the presence and absence of p53. Thus, it is our hypothesis that p53 loss contributes to tumor progression through a variety of mechanisms including the ones described here and those that are yet to be discovered. It is expected that the current p53-de®cient mice and new mutant versions (e.g. p53 alleles with point mutations or tissue-speci®c p53 deletions) will play an important role in elucidating some of these novel tumorigenic mechanisms.
RB-de®cient mice (inherited childhood retinoblastoma)
Childhood retinoblastoma has both an inherited and sporadic component. About 60% of cases are nonhereditary and 40% of cases are inherited (Newsham et al., 1998) . Positional cloning was used to clone the gene based on linkage analysis of familial retinoblastoma cases. The retinoblastoma susceptibility gene, RB, was cloned and characterized by a number of groups (Friend et al., 1986; Fung et al., 1987; Lee et al., 1987) . Both copies of the RB gene are inactivated by somatic mutations during the development of sporadic retinoblastomas, a malignant tumor arising from the nuclear layer of the retina (Bookstein et al., 1988; Horowitz et al., 1989; Dunn et al., 1989) . This gene is also mutated in many other sporadically arising tumor types, including osteosarcomas, soft tissue sarcomas and carcinomas of the breast, lung and bladder (Newsham et al., 1998) . Individuals who inherit a nonfunctional copy of RB have an estimated 90% probability of developing retinoblastoma at an early age (Knudson et al., 1991) . The RB gene product is a nuclear phosphoprotein, which shares homology with two additional family members, p107 and p130, neither of which seem to play a role in tumorigenesis (Weinberg, 1995) .
The RB protein is an important regulator of the G1 checkpoint. It binds to members of the E2F family, transcription factors needed for transcription of S phase early genes, and prevents S phase entry (Weinberg, 1995) . Hyper-phosphorylation of RB by G1/S cyclin-dependent kinases releases E2F from RBmediated repression and enables progression of the cell into S phase.
Rb-de®cient mice have been generated by at least three groups (Clarke et al., 1992; Lee et al., 1992; Jacks et al., 1992) . Mice that are homozygous for Rb de®ciency die at about day 14.5 of gestation. The hematopoietic system is abnormal in these mice, exhibiting a signi®cant increase in the number of immature nucleated erythrocytes. In addition, neurogenesis is defective as cells in the central and peripheral nervous system undergo extensive apoptosis and aberrant S phase entry. Interestingly, these apoptotic and proliferative eects were largely abrogated by introducting E2F-1 nullizygosity into the Rb7/7 embryos (Tsai et al., 1998) . In addition, the embryos had an extended viability, exhibiting embryonic lethality at 17.5 days gestation, rather than 14.5 days for the Rb7/7 embryos. These results indicate that the apoptosis induction occurring in Rb null cells is mediated largely by E2F-1 overexpression. Recent studies in an Rb-de®cient tumor model by Pan et al. (1998) have con®rmed that the absence of E2F-1 reduces apoptosis in a p53-dependent manner.
Given the signi®cant level of embryonic development and organogenesis observed in the Rb-de®cient embryos, despite the critical importance of Rb in mediating the G1/S transition, it could be argued that other Rb-related molecules might functionally compensate for Rb loss. In fact, two Rb family members which exhibit structural and biochemical similarities to Rb, p107 and p130, have been inactivated in the germ line of mice (Cobrinik et al., 1996; Lee et al., 1996) . p107 and p130 null mice develop normally, but doubly de®cient p1077/7; p1307/7 mice show neonatal lethality and bide®cient p1077/7; Rb7/7 mice show earlier embryonic lethality (11.5 days) than monode®cient Rb7/7 mice (Lin et al., 1996) . Thus, it appears likely that the Rb family members do have some overlapping functions as well as distinct functions.
Mice that are heterozygous for the Rb gene show no signs of retinoblastoma or precursor lesions. However, virtually all of the Rb heterozygotes develop pituitary adenomas Hu et al., 1994) . These tumors consistently show loss of heterozygosity of the wild-type Rb allele, consistent with Knudson's`two hit' hypothesis (Hu et al., 1994) .
The absence of retinoblastoma in these mice has been attributed to species dierences, such as differences in life span and number of cells in the target tissue. Interestingly, retinoblastoma has been observed in mice expressing SV40 T-antigen (which inactivates Rb) in the retina (Windle et al., 1990) . These results suggest that the development of retinoblastoma in mice requires inactivation of additional genes, possibly including p53 (Windle et al., 1990) . Indeed, p53 loss may be involved in retinoblastoma in mice, as expression of human papilloma virus E7 oncoprotein in the retinal cells, which binds and inactivates Rb protein only, results in retinal degeneration with high level of apoptosis, with the cells restricted from undergoing terminal dierentiation. However, expression of E7 in a null p53 background leads to retinoblastoma (Howes et al., 1994) .
Is there a synergistic interaction between p53 and Rb in other contexts of tumorigenesis? Doubly heterozygous p53 and Rb mice exhibit shorter life span and develop endocrine tumor not seen in the parental animals Harvey et al., 1995) . These in vivo demonstrations of Rb and p53 cooperativity con®rm the multilevel interactions of these two proteins observed in molecular studies. It has recently been demonstrated that E2F-1 upregulation (occurring during Rb de®ciency) stimulates p19ARF expression which in turn results in inhibition of mdm2 and stabilization of p53 . Moreover, a recent report revealed an apparent cross talk between p53 and RB during induction of apoptosis by p53 (Gottlieb and Oren, 1998) . Depletion of IL-3 from the medium of some tumor cell lines results in caspase-mediated RB cleavage, occurring preferentially within cells which express functional p53. Thus, p53 may modulate apoptosis both by diminishing the activity of Rb (which inhibits apoptosis), and by positive regulation of the apoptotic machinery itself through transcriptiondependent and independent mechanisms. p16 and p19ARF-de®cient mice (dysplastic nevus syndrome)
The incidence of melanoma has been increasing rapidly and 37 000 cases per year have recently been reported in the US (Kamb and Herlin, 1998) . Melanomas arise somatically from melanocyte precursor cells, but an inherited susceptibility to melanoma, called dysplastic nevus syndrome, has also been observed. The aected individuals in the melanoma-prone families have an estimated risk of developing a malignant melanoma of 53% by age 80 (Kamb and Herlin, 1998) . Genetic analysis of somatic and inherited melanomas showed frequent loss of heterozygosity at chromosome 9p21 (Fountain et al., 1992) . Studies of melanoma cell lines localized the deletions to a site containing two genes encoding the cyclin-dependent kinase inhibitors p16 and p15 Nobori et al., 1994; Jen et al., 1994) . Fine mapping studies showed that inactivating mutations were usually in the p16 locus, identifying it as a tumor suppressor and responsible for the majority of the melanoma-susceptible kindreds Liu et al., 1995; Stone et al., 1995) . The signi®cance of the p16 locus in tumor suppression was
Mouse tumor suppressor models N Ghebranious and LA Donehower underscored by the observation that it was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary and lymphocyte (Kamb and Herlin, 1998) . In addition, point mutations and small deletions are common in pancreatic adenocarcinomas, esophageal carcinomas, biliary tract cancers, and in families with hereditary susceptibility to melanoma and pancreatic cancer (Goldstein et al., 1995; Hussussian et al., 1994) .
The p16 (or INK4a) locus encodes two dierent transcripts each initiated by a distinct promoter (Duro et al., 1995; Stone et al., 1995; Mao et al., 1995) . Each transcript is composed of two common exons, E2 and E3, and two dierentially expressed ®rst exons, E1a or E1b. E1a is the exon encoded in the p16 transcript, whereas in p19ARF (alternative reading frame), it is E1b (Quelle et al., 1995) . Initiation from E1b results in a transcript of a dierent reading frame. Thus, p19ARF protein shares no homology with p16. p16 was ®rst found to be associated with CDK4 in human cells (Xiong et al., 1993) , and was cloned thereafter and characterized as a CDK4/6 inhibitor (Serrano et al., 1993) .
The p16 protein induces G1 arrest through its direct binding to CDK4/6 molecules. This growth suppression is mediated by RB, since overexpression of p16 results in G1 arrest only in cells with functional RB (Guan et al., 1994; Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995; Serrano et al., 1995) . p19ARF, the alternative product of the p16INK4a locus, has the ability to arrest cell proliferation both at G1 and G2 phases of the cell cycle. However, the mechanism for such suppression does not involve direct inhibition of any of the known CDKs (Quelle et al., 1995) . More recently, it was shown that p19ARF potently suppresses oncogenic transformation in primary cells and that this function is abrogated when p53 is neutralized by viral oncoprotein and dominantnegative mutants, but not by the p53 antagonist mdm2 (Pomerantz et al., 1998; Kamijo et al., 1998; Zhang et al., 1998 ). p19ARF appears to block the mdm2-induced degradation of p53 through physical interaction with Mdm2 (Prives, 1998) .
INK4a-de®cient mice have been generated using gene targeting techniques in ES cells. The targeting resulted in the deletion of exons 2 and 3 of the INK4a locus, thus disrupting both p16 as well as p19ARF protein function (Serrano et al., 1996) . The homozygous null INK4a7/7 mice develop normally and are fertile. Spontaneous tumors, mostly sarcomas and lymphomas, develop by approximately 30 weeks of age in about 68% of the null mice. The INK4a7/7 mice display features consistent with abnormal extramedullary hematopoisis, suggesting that p16 or p19ARF may normally regulate the proliferation of some hematopoietic lineages or their progenitors. Unlike humans, none of the null mice developed skin melanoma, which could be due to the fact that mice are relatively resistant to the development of cutaneous melanomas. Analysis of mouse embryonic ®broblasts (MEFs) obtained from INK4a7/7 mice established that these cells have a high proliferation index as well as colony formation eciency (Serrano et al., 1996) .
More recently, Kamijo et al. (1997) targeted the INK4a locus in a dierent way, disrupting the p19ARF gene but not p16. This was accomplished by deleting exon E1b, while leaving all of the p16INK4a coding sequence intact. Surprisingly, p19ARF-de®cient mice develop tumors early in life in a manner similar to INK4a-de®cient mice. One third of the p19ARF7/7 null mice exhibited malignant tumors by 6 months of age (mostly, ®brosarcomas and lymphomas), but no tumors were observed in the p19ARF+/+ or p19ARF+/7 mice. Following dimethylbenzanthracene (DMBA) treatment, skin tumors develop by 13 ± 15 weeks of age in p19ARF null mice but not in control groups (Kamijo et al., 1997) .
Interestingly, MEFs derived form p19ARF7/7 embryos, unlike p19ARF+/7 and p19ARF+/+ MEFs, proliferate faster and do not undergo any detectable senescence even up to ten passages. However, they promptly stop proliferating when infected with a retrovirus encoding p19ARF. It is noteworthy, that p537/7 MEFs also do not undergo any senescence (Harvey et al., 1993) . Thus, the eect observed of p19ARF on cell growth could be mediated by p53 either directly or through p21 WAF1/CIP1
. Consistent with this hypothesis is the observation that basal p21 WAF1/CIP1 levels are reduced in p19ARF7/7 MEFs compared to p19ARF+/+ MEFs (Kamijo et al., 1997) , which is further supported by the recent ®nding that p19ARF physically interacts with mdm2 and prevents it from complexing with p53 and inactivating it (Pomerantz et al., 1998; Kamijo et al., 1998; Stott et al., 1998; Zhang et al., 1998) .
The similarity between the INK4a and the p19ARF mouse models raises an important question about the relative contributions of p16 and p19ARF in tumorigenesis. In human tumors, mutations aecting both alleles are often observed, as well as mutations in only the p16 allele. However, p14ARF (the human version of mouse p19ARF) mutations are infrequently observed in human tumors (Haber, 1997) . Thus, the generation and characterization of a mouse with a p16-speci®c mutation may be important in further clarifying some of these issues.
Apc-de®cient mice (familial adenomatous polyposis)
Colon cancer is one of the most frequently arising malignancies in the western world, with an estimated 60 000 deaths per year in the United States alone (Kinzler and Vogelstein, 1998) . In one form of colon cancer, familial adenomatous polyposis (FAP), the individual inherits a single mutant allele of the adenomatous polyposis coli gene (APC) and develops hundreds of polyps in the colon (Bulow, 1987 Joslyn et al., 1991; Powell et al., 1992) . Some of these polyps may eventually progress to a malignant carcinoma form (Bulow, 1987) . APC mutations also frequently occur in sporadically arising colon carcinomas (Kinzler and Vogelstein, 1998) . Mutation and loss of both APC alleles are often a relatively early event in colon polyps (Kinzler and Vogelstein, 1998) .
The human APC gene was identi®ed by positional cloning Kinzler et al., 1991; Nishisho et al., 1991) . The gene encodes a large 2844 amino acid multi-domain polypeptide, which is highly conserved between human and mouse Kinzler et al., 1991; Su et al., 1992) . The APC protein was shown to bind to beta-catenin, microtubules and an uncharacterized protein named EB1 (Joslyn et al., 1993; Munemitsu et al., 1994 Munemitsu et al., , 1995 Rubin®eld et al., 1995 Rubin®eld et al., , 1996 Su et al., 1993) . Accordingly, the APC protein may be involved in cellular adhesion, migration, signaling and proliferation (Hoscheutzky et al., 1994; Nathke et al., 1996; Rubinfeld et al., 1996; Wong et al., 1996) .
The ®rst Apc-de®cient mice were not generated by gene targeting methods, but by a mouse germ line random mutagenesis protocol emplying ethylnitrosurea, a point mutagen. One line of mutagenized mice, called Min (Multiple intestinal neoplasms) displayed an anemic pheotype, which was traced to bleeding from multiple polyps in the intestine (Moser et al., 1990) . The Min phenotype resembled that of FAP. This resemblance led to the characterization of the Min mutation as a nonsense mutation in the mouse Apc homologue. (Su et al., 1992) . The heterozygous mice rarely live beyond 5 months of age, due to secondary eects to the tumors including anemia and intestinal blockage (Moser et al., 1990) . The intestinal tumors invariably show loss of the remaining wild type allele (Luongo et al., 1994; Levy et al., 1994) . In addition, the Apc protein has been shown to be important in development as homozygosity of the Min mutation leads in early embryonic lethality .
The phenotype of these mice diers from the human FAP phenotype in a few aspects, among which are the origin of the tumor. In the Min mice, tumors appear in the small intestine, whereas in human FAP patients, the majority of tumors develop in the large intestine (Bilger et al., 1996) . In addition, about 10% of female Min mice develop mammary tumors, which has not been seen in human FAP patients . It should be noted that a large majority of the FAP patients develop additional complications not seen in Min mice, such as bone and body wall tumors, skin cysts and enlarged pigmented retinal cells (Bullow, 1987) . The lack of extra-intestinal lesions, such as that seen in FAP patients, in the Min mouse model is attributed to the involvement of genes other than Apc in the process of tumorigenesis. In favor of this argument is the observation that Min/+, p537/7 mice develop pancreatic cancer and some of the body wall lesions seen in FAP patients W Dove, personal communication) .
Apc-de®cient mice have also been generated using gene targeting (Oshima et al., 1995) . The targeting resulted in the truncation of the Apc gene product at amino acid 716. The heterozygous mice develop multiple polyps throughout the small intestine, similar to that seen in Min mice. Tumor analysis indicated that the wild-type Apc gene is lost during tumorigenesis (Oshima et al., 1995) . The homozygous mice, as with the Min mice, die in utero before day 8 of gestation. To circumvent embryonic lethality due to the Apc de®ciency in mice, Shibata et al. (1997) used a conditional gene targeting system. Using the Cre-loxP system, the Apc gene was inactivated speci®cally in the colorectal epithelium by inserting loxP sites in the introns around exon 14 of the Apc gene, and introducing the mutant allele into the mouse germline. Mice homozygous for Apc-loxP insertion were normal. However, upon infection of the colorectal region with an adenovirus encoding the Cre recombinase, the mice developed adenomas within 4 weeks. The adenomas showed deletion of Apc exon 14, indicating that the loss of Apc function was caused by Cre-loxP-mediated recombination (Shibata et al., 1997) .
Intercrossing of C57BL/6 Min mice with other strains has revealed modi®er loci which speci®cally aected the polyp numbers and Min-induced morbidity (Bilger et al., 1996) . Sensitive strains for Mom1 (e.g. C57BL/6) developed higher numbers of polyps than were observed for resistant strains (e.g. AKR). One of the major tumor modi®ers identi®ed was the Mom1 (Modi®er of Min 1) locus. Mapping studies showed that Mom1 segregated with markers on the distal end of mouse chromosome 4 (Dietrich et al., 1993 (Bilger et al., 1996; Shoemaker et al., 1998) .
Nf1 and Nf2-de®cient mice (neuro®bromatosis type 1 and type 2)
The neuro®bromatoses are genetic disorders that primarily aect cell growth of neural tissues. The most common type, neuro®bromatosis type 1 (NF1), is an autosomal dominant disorder aecting about 1 in 3000 individuals (Gutmann and Collins, 1998) . These disorders can cause benign tumors to grow from nerves at any location, most commonly in Schwann cells. A subset of these tumors may also progress into malignant neuro®brosarcomas. Moreover, multiple hyperpigmented areas, also called`cafe au lait macules', are a common characteristic in these patients. NF-1 patients are also at risk for developing malignant myeloid disorders as well as optic gliomas and pheochromocytomas (Hope and Mulvihill, 1981) . Likewise, infants and children with NF1 are at high risk of developing malignant myeloid disorders (Bader and Miller, 1978) .
The NF1 gene was identi®ed in 1990 by positional cloning (Viskochil et al., 1990; Wallace et al., 1990) . The gene is more than 300 kb long, composed of about 50 exons, and encodes a protein, neuro®bromin, of 2818 amino acids. Neuro®bromin has extensive homology with the catalytic region of the RAS GTPase-activating protein, GAP, and the IRA1 and IRA2 gene products of the yeast S. cerevisiae (Ballester et al., 1990) . This GAP domain functions to negatively regulate Ras by catalyzing the conversion of the active GTP-bound form of Ras to the inactive GDP-bound form (Hall, 1990) . The NF1 gene is presumed to follow Knudson's two hit rule, since the majority of germ line NF1 mutations produce no protein, and clonally derived malignant neuro®brosarcomas express no detectable NF1 protein (Basu et al., 1992; DeClue et al., 1992) .
Two research groups have reported the targeted disruption of the Nf1 gene in the mouse germ line (Brannan et al., 1994; . Mice homozygous for the Nf1 mutation die during development between days 12.5 and 14 of gestation. The cause of early lethality has been attributed to a cardiac dysfunction, in which several abnormalities in the heart exist, including disoriented and poorly developed myocardial ®bres, overall hypoplasticity, and ventricular septal defects caused by insucient ventricular growth and abnormalities in valve lea¯et formation. These defects indicate that neuro®bromin has an important role in heart development. This idea is further supported by the observation of high levels of neuro®bromin in the heart during during developmental periods that coincide with the development of the abnormalities (Huynh et al., 1994; Brannan et al., 1994) . Brannan et al. (1994) also reported a delay in renal, hepatic as well as skeletal muscle development in the Nf1 null mice.
Mice heterozygous for the Nf1 mutation have do not develop neuro®bromas or pigmentation defects such as that seen in humans (Brannan et al., 1994; . Nevertheless, the loss of one Nf1 allele seems to increase the overall rate of tumor development in the mouse. About 19% of the heterozygotes develop pheochromocytoma, which aects about 1% of the NF1 patients, as well as myeloid leukemias. These tumors displayed loss of heterozygosity for the wildtype Nf1 allele, which is also common among human NF1 patients . However, despite the lack of neuro®bromas in the Nf1+/7 animals, chimeric mice containing a mixture of normal cells and Nf17/7 cells did develop neuro®bromas similar to that seen in human NF1 patients, but not of Schwann cell origin, as is the case in humans (Cichowski et al., 1996) .
Even though the Nf17/7 mice die early during development, transplantation of hematopoietic cells from the Nf17/7 embryos into lethally irradiated mice resulted in chronic myeloid leukemias derived from the donor Nf1-de®cient cells (Largaespada et al., 1996) . Hematopoietic cells derived from fetal liver of Nf17/7 mouse embryos were shown to have a selective hypersensitivity to GM-CSF, a feature shared with leukemic cells derived from NF1 patients (Bollag et al., 1996; Largaespada et al., 1996) . The elevated levels of Ras-GTP and the reduction in Nf1-GAP activity are likely to be the cause of GM-CSF hypersensitivity, as well as for the development of myeloid neoplasms.
Neuro®bromatosis type 2 (NF-2), is an autosomal dominant disorder aecting about 1 in 50 000 individuals. It causes benign tumors in the nervous system including Schwanomas, meningiomas, and ependymonas (MacCollin and Gusella, 1998) . Mutations and loss of heterozygosity of the NF2 locus are common in NF2 patients with sporadically occurring tumors, suggesting that NF2 behaves as a classical tumor suppressor gene (MacCollin and Gusella, 1998) . The NF2 gene was cloned using positional cloning (Rouleau et al., 1993) . The protein product has homology with proteins at the plasma membrane and cytoskeleton interface and was named merlin (meosin, ezrin, radixin like protein). The NF2 protein is thought to be involved in cytoskeletal reorganization events.
More recently, Jacks and colleagues used gene targeting techniques to disrupt the Nf2 gene in mouse ES cells (McClatchey et al., 1997) . The homozygous mutation at the Nf2 locus leads to embryonic failure at embryonic day (E) 6.5 ± 7.0, with the embryos displaying poorly developed extraembryonic structures and a lack of organized extraembryonic ectoderm (McClatchey et al., 1997) .
The Nf2 heterozygous mice are predisposed to a broad spectrum of malignant tumors, though these tumors develop relatively late in the mouse life span (mean incidence at 22 months of age) (McClatchey et al., 1998) . The tumor spectrum was quite varied, though osteosarcomas were the most frequently observed and arose in 63% of the Nf2+/7 mice. Surprisingly, none of the tumor types observed in the heterozygous mice resembled the tumor spectrum observed in NF2 patients, and were much more malignant in nature than the relatively benign human neoplasms. Interestingly, unlike tumors in p53-de®cient mice (Taverna et al., 1998) and wild type mice (Frith et al., 1981) , the Nf2+/7 tumors were highly metastatic, with metastatic lesions frequently found in the lung and liver as well as other sites (McClatchey et al., 1998) . McClatchey et al. (1998) also demonstrated linkagespeci®c eects of Nf2 and p53 cooperativity in tumorigenesis. In the mouse, the Nf2 gene and p53 gene are both located on chromosome 11 about 40 cm apart. Doubly de®cient Nf2+/7; p53+/7 mice with the two mutant alleles in cis (on the same chromosome) or in trans (on separate chromosomes) were monitored for tumors. Heterozygotes with the mutant alleles in cis demonstrated dramatically accelerated tumor formation compared to the mice with trans con®guration of mutant alleles. However, even the trans double heterozygotes showed accelerated tumor formation compared to the parental p53+/7 and Nf2+/7 mice, indicating a marked cooperativity between these two tumor suppressor genes.
BRCA1 and BRCA2-de®cient mice (inherited breast cancer susceptibility)
The tumor suppressor genes BRCA1 and BRCA2 have been implicated in inherited predisposition to breast cancer (Miki et al., 1994; Cannon-Albreight and Skolnick, 1996; Claus et al., 1991; Easton et al., 1993; Marcus et al., 1996; Stratton and Wooster, 1996; Szabo and King, 1995; Couch and Weber, 1998) . Mutations of BRCA1 also predispose to ovarian cancer (Gayther et al., 1995; Johannsson et al., 1996; Serova et al., 1996) , whereas, mutations in BRCA2 predispose to male breast cancer as well as pancreatic cancer (Goggins et al., 1996; Schutte et al., 1995; Teng et al., 1996) .
Nearly 45% of all familial breast cancer cases have mutations in BRCA1 or BRCA2, while mutations of these genes are infrequent in sporadic non-familial breast tumors (Lancaster et al., 1996; Miki et al., 1994; Teng et al., 1996) . Both BRCA1 and BRCA2 are considered tumor suppressor genes due to the frequent loss of heterozygosity of the wild-type allele in tumors Mouse tumor suppressor models N Ghebranious and LA Donehower from patients with germ line mutations in BRCA1 or BRCA2 Collins et al., 1995) . Interestingly, there is some similarity in the biochemical properties in the protein product of these two genes, both have transcription activation function (Chapman et al., 1996; Milner et al., 1997) and can colocalize with Rad51, a protein involved in the regulation of recombination and double stranded DNA repair, suggesting that these two genes may function in DNA repair (Sharan et al., 1997; Scully et al., 1997) . Moreover, BRCA2 appears to directly complex with Rad51 (Sharan et al., 1997) . In addition, both genes are coordinately regulated during development (Blackshear et al., 1998) , and both gene products form a stable interaction in mitotic and meiotic cells .
Given their potential role in DNA repair, both BRCA1 and BRCA2 proteins have been referred to as caretakers' rather than`gatekeepers', which tend to be associated with direct cell cycle control (Kinzler and Vogelstein, 1997) . In this respect, inactivation of BRCA1 or BRCA2 does not promote tumor initiation directly, but rather facilitates genetic instability and mutations of genes, speci®cally, the gatekeeper genes. This interpretation is consistent with the ®ndings that BRCA1 and BRCA2 interact with Rad51, and the similarities in the sensitivity of their null mice to radiation. Moreover, mutations in`caretaker' genes occur primarily as germ line mutations in inherited cancer syndromes and are less frequent in somatically arising tumors Kinzler and Vogelstein, 1997) . Thus, the primary role of BRCA1 and BRCA2 in tumor suppression may be through promotion of DNA repair, rather than through arrest of cell proliferation. Nevertheless, recent data implicates BRCA1 in cell cycle control as transfection of BRCA1 into cancer cells inhibits S phase entry through induction of p21 WAF1/CIP1 (Somasundaram et al., 1997) . In addition, BRCA1 has been reported to associate with p53 and stimulate its transcriptional activity (Zhang et al., 1998) .
Multiple groups have reported the disruption of the Brca1 gene in the mouse (Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997) . Homozygous Brca1 mutant mice die before day 7.5 of embryogenesis. Mutant mice are poorly developed, with no evidence of mesoderm formation. An interesting observation in these mice is that they show reduced cell proliferation together with high expression of the CDK inhibitor, p21
. This observation suggests that the death of the mutant embryos are due to failure in the proliferation needed for the establishment of the dierent germ layers (Hakem et al., 1996) .
Gene targeting which leads to early truncation of The Brca2 gene leads to embryonic lethality in mouse (Sharan et al., 1997; Suzuki et al., 1997) . The embryos arrest at the same time as the onset of detectable Brca2 expression after day 6.5 of gestation. Like Brca1-de®cient mice, apoptosis is normal in Brca2 null mice, whereas cellular proliferation is impaired (Sharan et al., 1997; Suzuki et al., 1997) . Interestingly, Brca2-de®cient mice exhibit increased sensitivity to radiation (Sharan et al., 1997) , which is a feature shared with Rad51-de®cient mice (Lim et al., 1996) .
More recent targeting experiments in the Brca2 gene utilizing smaller C-terminal truncations in the encoded protein have resulted in homozygous mice that are viable (Connor et al., 1997; Friedman et al., 1998) . These mice are approximately one-third normal size and are susceptible to thymic lymphomas rather than mammary tumors. Embryo ®broblasts derived from the homozygous mice are defective in proliferation and display a progressively reduced growth rate with passaging. Patel et al. (1998) have shown that the Brca2 homozygous cells exhibit spontaneous chromosomal abnormalities, with frequent formation of triradial and quadriradial chromosomes. These structures are thought to arise through aberrant chromosome exchanges and are also observed in Rad51-de®cient cells. Such results indicate that Brca2 and Rad51 are important in maintaining correct chromosome segregation and resolution of recombination intermediates during meiosis and mitosis. Interestingly, the increased appearance of these aberrant structures was also correlated with high levels of p53 and p21
, indicating a stimulated DNA damage response.
Two groups have demonstrated a partial rescue of the Brca1 and Brca2 null embryonic lethality through simultaneous mutation of p53 (Hakem et al., 1996; Ludwig et al., 1997) . Double mutant embryos in Brca1 and p53 or Brca2 and p53 survive an additional one to two days of gestation, suggesting perhaps that activation of p53 activity by defective DNA repair in the Brca-de®cient embryo may inhibit proliferation during development and induce earlier abnormalities. In support of this hypothesis is the observation that mutation of p21 WAF1/CIP1 has been shown to be capable of delaying the Brca1 null mouse embryonic lethality .
Surprisingly, both Brca1 and Brca2 heterozygous mice do not exhibit any cancer predisposition (Hakem et al., 1996; Lim et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Sharan et al., 1997; Suzuki et al., 1997) . This dierence between mouse and man may relate a number of potential explanations, including the diering functional activities of the murine and human Brca proteins, to the dierences in life span between mouse and human, or to a greater resistance to Brca LOH in murine tissues. Carcinogen treatment or crosses of the Brca1 and Brca2 heterozygous mice to other tumor-susceptible mice may yet reveal some tumorigenic predisposition.
WT-1 de®cient mice (Wilms' tumor)
Urogenital malformations as well as the appearance of childhood tumors of the kidney are caused by mutations in the Wilms' tumor-associated gene, WT-1 (Baird et al., 1992; Bruening et al., 1992; Cowell et al., 1991; Davis et al., 1991; Haber et al., 1990; Hu et al., 1991; Little et al., 1992; Pelletier et al., 1991a; Ton et al., 1991; van Heyningen et al., 1990) . Consistent with this phenotype, the WT-1 gene has been shown to be involved in the urogenital development (Pelletier et al., 1991b , Pritchard-Jones et al., 1990 .
The WT-1 gene maps to the short arm of chromosome 11. Wilms' tumors show cytogenetically visible deletions as well as loss of heterozygosity at the WT-1 locus, suggesting that these tumor suppressor gene follows Knudson's two hit rule (Knudson, 1985; Haber and Housman, 1992) . The gene product of WT-1 is a proline/glutamine rich amino terminal domain protein, which contains four zinc ®nger domains at the carboxy terminal (Buckler et al., 1991; Call et al., 1990; Morris et al., 1991) . In addition, the WT-1 protein has homology to the EGR family of transcription factors, and has been shown to transcriptionally repress genes with the EGR-1 recognition sites (Drummond et al., 1992; Call et al., 1990) .
In 1993, Kreidberg et al. (1993) successfully disrupted the Wt-1 gene in mice using gene targeting technique in ES cells. Homozygous mice for the Wt-1 mutation die at day 11 of gestation of kidney and gonad developmental failure. In addition, the mutation revealed developmental abnormalities in the mesothelium, heart, and lungs. Despite the clear role of Wt-1 in development, mice heterozygous for the Wt-1 mutation do not develop tumors.
VHL-de®cient mice (von Hippel-Lindau syndrome)
Inheritance of an inactivated form of the VHL tumor suppressor gene predisposes patients to develop von Hippel-Lindau disease. The disease is characterized by development of tumors at multiple sites, including retinal angiomas, hemangioblastomas of the central nervous system, pheochromocytomas, renal cell carcinomas, and pancreatic cancers (Gnarra et al., 1996; Linehan and Klausner, 1998) . Moreover, somatic mutations in one allele of the VHL gene and inactivation of the other through hypermethylation or mutation, occurs in approximately 80% of sporadic clear cell renal carcinoma (Gnarra et al., 1996; Linehan and Klausner, 1998) .
Like most tumor suppressor genes, the human VHL gene has been identi®ed by positional cloning (Latif et al., 1993) . The VHL protein structure has been deduced and was shown to physically interact with elongin B and elongin C, RNA polymerase II elongation factors. Loss of VHL appears to result in an inappropriate increase in hypoxia-inducible mRNAs, which may account for the high degree of vascularization of VHL-associated cancers . In addition, the elongin-VHL complex was shown to interact with a human homologue of a member of a conserved gene family, CUL-2, involved in cell cycle and growth control Duan et al., 1995; Kibel et al., 1995; Pause et al., 1997) . Introduction of wild type VHL into VHL-negative renal carcinoma cells suppresses their growth rate by causing them to exit the cell cycle into G0/quiescence (Pause et al., 1998) .
Gene targeting techniques have been employed to inactivate the VHL gene in the germ line of mice (Gnarra et al., 1997) . Heterozygous mice developed normally and showed no phenotype, whereas mice that are homozygous for Vhl deletion die between days 10.5-12.5 in utero. The likely cause of death in these mice was attributed to inadequate vasculogenesis in the placenta, a phenotype consistent with the involvement of VHL in regulating levels of angiogenesis-associated mRNAs (Gnarra et al., 1997) . One interesting aspect of ®broblasts derived from VHL null embryos was a gross defect in ®bronectin matrix assembly, indicating that VHL may also have an extracellular role .
PTEN-de®cient mice (Cowden syndrome)
PTEN (for`phosphatase and tensin homologue deleted from chromosome 10') has recently been identi®ed as a candidate tumor suppressor gene and has been found to be mutated in gliomas (Rasheed et al., 1997) , endometrial tumors (Tashiro et al., 1997) , prostate cancers (Cairns et al., 1997) , and breast cancers (Rhei et al., 1997) . Germ line mutations in the PTEN gene have been associated with Cowden disease, an inherited cancer predisposition syndrome characterized by early development of breast, thyroid, and brain tumors (Eng and Parsons, 1998) . Two related familial syndromes, Lhermitte-Duclos disease and Bannayan-Zonana syndrome, show similar predispositions to tumors as Cowden disease and have germ line PTEN mutations, but have some developmental dierences which distinguish them from one another (Zonana et al., 1976; Eng et al., 1994) .
The pTEN gene encodes a protein with homology to dual speci®city protein phosphatases and tensin, a protein associated with the cytoskeleton at focal adhesions (Eng and Parsons, 1998) . PTEN interacts with focal adhesion kinase and reduces its phosphorylation. It was also shown to reduce cell migration, formation of focal adhesions, and extracellular matrix interactions (Tamura et al., 1998) . It is the ®rst example of a classical tumor suppressor that is a phosphatase.
Recently, PTEN-de®cient mice have been generated by Di Cristofano et al. (1998) and Stambolic et al. (1998) . PTEN null embryos displayed an early embryonic lethal phenotype. Interestingly, the null embryos exhibited a dramatic overgrowth in the cephalic and caudal regions. Moreover, BrdU labeling assays indicated a signi®cantly higher proliferative index in the cells of the developing null embryo compared to its wild type siblings (Stambolic et al., 1998) . Despite the enhanced proliferation of PTEN null cells in vivo, ES cells and ®broblasts derived from these embryos showed no enhanced proliferation. ES cells, however, did exhibit enhanced anchorageindependent cell growth (Di Cristofano et al., 1998) . Moreover, ®broblasts showed greatly decreased susceptibility to apoptosis following treatment with a variety of apoptosis-inducing agents. This reduction in apoptosis was traced to reduced levels of dephosphorylation and increased kinase activity of protein kinase B/Akt, a kinase which mediates cell survival (Stambolic et al., 1998) . Increased kinase activity of protein kinase B protects cells from apoptosis induced by withdrawal of survival signals. Thus, absence of PTEN may contribute to tumorigenesis either through increasing cell proliferation rates (as observed in the early embryos), by protection against apoptosis (as observed in the MEF studies), or by increased invasiveness consistent with the enhanced anchorage independence observed in PTEN7/7 ES cells.
Con®rmation that PTEN mutations can predispose to cancer was demonstrated by the fact that PTEN+/ 7 mice are susceptible to early tumors. Stambolic et al. (1998) noted a frequent development of T cell lymphomas, while Di Cristofano et al. (1998) described a broader array of tumor types, including apparent colon adenocarcinomas, leukemia, and germ cell tumors. However, they also observed hyperplasias and dysplasias of the prostate, skin, and colon, which are characteristic of the three syndromes with PTEN germ line mutations. The PTEN+/7 T-cell lymphomas of Stambolic et al. (1998) were associated with PTEN loss of heterozygosity, whereas the various PTEN+/7 tumors described by Di Cristofano et al. (1998) appeared to retain the wild type PTEN allele. However, the structural integrity of the PTEN allele at the nucleotide level and its expression in these tumors remain to be determined. Stambolic et al. (1998) concluded that PTEN belongs to the`gatekeeper' category of tumor suppressor genes as it directly aects cell growth regulatory pathways.
Conclusions
The mouse tumor suppressor models described here have an array of interesting phenotypes that have shed new light on the role of these genes in embryonic development, cell cycle regulation, and tumor suppression. In addition, the crossing of these models to each other and to other informative models has facilitated the study of the cooperativity of dierent combinations of tumor suppressors and oncogenes in embryogenesis and tumorigenesis.
One of the rationales for generating these mice is that they may serve as a useful model for the corresponding human inherited cancer syndrome. As can be seen in Table 1 showing the tumor spectra observed in the mouse models, the mice have achieved varying levels of success in emulating the cognate human inherited cancer predisposition. In Table 1 we have grouped the mouse models according to the similarity of the tumor types observed in the heterozygous mice with those in the corresponding human syndrome. As indicated, Apc, p53, Nf1, and PTEN heterozygotes (Group I) exhibit some degree of correlation. Li-Fraumeni syndrome patients and p53+/7 mice both show frequent development of osteosarcomas, soft tissue sarcomas, and hematopoietic neoplasms (Malkin, 1998) . However, the correlation is imperfect, since Li-Fraumeni patients exhibit frequent breast tumors and brain tumors, which are relatively rare in the p53+/7 mice (Malkin et al., 1990; Donehower, 1996) . Familial adenomatous polyposis patients develop carcinomas in the large intestine, while Min mice develop tumors exhibit tumors in the small intestine, which should be considered a relatively minor dierence with respect to the Min mice serving as a useful model (Bilger et al., 1996) . Nf1 heterozygotes and NF1 patients both show a susceptibility to pheochromocytomas and myeloid leukemia, though Nf1+/7 mice fail to develop neuro®bromas, the signature tumor of NF1 patients (Cichowski et al., 1996) . However, chimeric mice composed of Nf17/7 cells have been developed and these have displayed neuro®broma-like lesions along various nerves of the peripheral nervous system (Cichowski et al., 1996) . Finally, PTEN heterozygotes exhibited thyroid and colon tumors and prostate, skin and colon dysplasias, which are characteristic of Cowden disease patients (Di Cristofano et al., 1998; Eng and Parsons, 1998) .
Group II mice represent those heterozygous models that develop tumors, but not of the same type observed in the cognate human syndrome. This category (Newsham et al., 1998) . The Nf2 heterozygotes succumb to malignant and metastatic osteosarcomas, lymphomas, lung adenocarcinomas, and liver tumors rather than to the relatively benign tumors of the central nervous system seen in NF2 aected humans (McClatchey et al., 1998; MacCollin and Gusella, 1998) . Thus, while the group II mice may not be useful in modeling speci®c tumors for the human syndrome, the very fact that they develop tumors makes them quite useful for investigating the underlying molecular mechanisms by which their tumor suppressor lesions predispose to early cancers. p16 and p19ARF-de®cient mice could be considered to be members of Category III. Cancers have not been reported for the heterozygous p16 and p19ARF mice, but the nullizygous animals do develop tumors (sarcomas and lymphomas) unlike those observed in the melanoma prone human syndrome (Kamb and Herlyn, 1998) .
The ®nal category, Group IV, is composed of models in which no tumors above background levels have been observed in the heterozygotes. This group includes the Brca1, Brca2, Vhl, and Wt-1 heterozygotes. It may be possible to show accelerated tumors in mice of this category through carcinogen protocols or through crosses to other tumor-suceptible models.
A number of explanations have been proposed for the lack of correlation in tumor phenotypes between mouse and human (Jacks, 1996) . The species-speci®c dierences could be a result of relatively subtle dierences in growth control pathways in mouse and human cells in particular tissues. Alternatively, the dierences could be explained by species-dependent dierences in susceptibility to loss of the remaining wild type tumor suppressor allele. Or perhaps the reduced target cell number or shorter life span of mice aect susceptibility in certain tissues. Moreover, the propensity of many of the tumor suppressor-de®cient mouse models to develop lymphomas and sarcomas may merely re¯ect the fact that the C57BL/6 strain into which the mutated alleles are usually crossed are highly susceptible to these tumor types. Thus, the tumor suppressor lesions in the mice may greatly exacerbate an earlier predisposition. The crossing of these lesions into dierent strains may alter the tumor spectra and provide the foundation for identifying novel tumor modi®er loci, as has been demonstrated by Dove (Bilger et al., 1996) .
In summary, we have described the developmental and tumorigenic consequences of mouse germ line mutations in the`gatekeeper' category of tumor suppressors for which there is a corresponding defect in a human inherited cancer syndrome. As we have seen, the tumor suppressor-de®cient mice and the cells derived from them have provided excellent tools for the development of critical new insights into tumor suppressor function. As new human tumor suppressors are identi®ed, mouse knockout models for these new genes will be generated and further conceptual advances will be made. Moreover, the development of second generation gene targeting technologies have made it possible to make more subtle gene alterations or conditional lesions that can provide more functional information beyond that provided by the mice with simple null alleles. The next several years promise to be very exciting ones in the development of mouse models for tumor suppressors.
